TuHURA appoints Dr. Craig Tendler (ex-J&J oncology VP) to Board, effective March 10, 2025

TuHURA Biosciences, Inc./NV

Dr. Tendler oversaw 30 major oncology drug approvals at J&J, including DARZALEX, ZYTIGA, and BALVERSA.
Received option to purchase 151,883 shares of HURA common stock at closing price on grant date.
TuHURA plans to begin Phase 3 trial of IFx-2.0 in Q2 2025; Tendler's experience expected to aid regulatory strategy.
Board expanded from five to six members with this appointment.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Craig Tendler

Director

HURA · TuHURA Biosciences, Inc./NV

Effective: 2025-03-10
Filed: March 12, 2025, 7:59 PM ET

On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Craig Tendler was appointed as Director at TuHURA Biosciences, Inc./NV.

Action: appointed
Role: Director

Exact text from the filing

On March 7, 2025, the Board of Directors (the “Board”) of TuHURA Biosciences, Inc. (the “Company”) increased the size of the Board from five members to six members and appointed Dr. Craig Tendler to the Board, effective as of March 10, 2025, to serve as a director until the Company’s 2025 Annual Meeting of Stockholders and until his successor has been duly elected and qualified or until his earlier death, resignation or removal.

View on SEC.gov

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-25-037600

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.